Skip to main content

Table 1 Patient characteristics

From: Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study

 

RA

AS

PsA

All

p value

RA/AS/PsA

Number, n (%)

53

24

8

85

 

Age, median (IQR)

61.0 (56.0–68.0)

59.5 (53.5–64.0)

62.0 (56.3–66.5)

61.0 (56.0–67.0)

0.26

Sex female/male, n (%)

40/13 (75.5/24.5)

8/16 (33.3/66.7)

3/5 (37.5/62.5)

51/34 (60.0/40.0)

0.001

Disease duration, median (IQR)

16.0 (8.0–22.8)

23.5 (11.5–30.0)

14.0 (4.0–30.5)

18.0 (8.3–26.0)

0.29

DAS28, mean ± SD

2.51 ± 0.88

–

–

–

–

ASDAS, mean ± SD

–

5.96 ± 2.95

–

–

–

CVD risk factors

 Smoke, n (%)

10 (18.9)

3 (12.5)

1 (12.5)

14 (16.5)

0.75

 BMI, mean ± SD

25.1 ± 3.3

25.2 ± 2.6

25.9 ± 2.9

25.2 ± 3.1

0.81

 TC (mmol/L), mean ± SD

6.41 ± 1.20

6.25 ± 0.87

6.24 ± 1.17

6.35 ± 1.11

0.81

 HDL-c (mmol/L), mean ± SD

1.83 ± 0.53

1.53 ± 0.43

1.45 ± 0.31

1.71 ± 0.50

0.02

 TG (mmol/L), median (IQR)

1.21 (0.89–1.57)

1.44 (1.02–1.99)

1.13 (0.78–2.70)

1.22 (0.89–1.75)

0.40

 LDL-c (mmol/L), mean ± SD

3.98 ± 1.09

4.03 ± 0.85

4.10 ± 0.97

4.01 ± 1.01

0.95

 sBP (mmHg), mean ± SD

142.8 ± 21.7

144.8 ± 14.3

151.1 ± 25.3

144.1 ± 20.2

0.55

 dBP (mmHg), mean ± SD

83.2 ± 9.2

84.6 ± 8.5

88.5 ± 11.5

84.1 ± 9.3

0.30

Comorbidities, n (%)

 HT

32 (60.4)

17 (70.8)

6 (75.0)

55 (64.7)

0.55

 Diabetes

4 (7.5)

2 (8.3)

1 (12.5)

7 (8.2)

0.84

 CVD

5 (9.4)

4 (16.7)

0 (0)

9 (10.6)

0.38

 CP, median (range)

1.0 (1.0–2.0)

1.0 (1.0–3.0)

2.5 (2.0–3.0)

1.0 (1.0–2.0)

0.09

Biomarkers, mean ± SD

 ESR (mm/h)

15.1 ± 10.3

16.2 ± 10.5

12.4 ± 9.8

15.9 ± 10.1

0.32

 White blood cells (109/L)

7.38 ± 2.97

7.74 ± 3.44

6.68 ± 1.72

6.67 ± 1.37

0.54

 CRP (mg/L), median (IQR)

3.00 (1.00–4.00)

1.00 (1.00–3.00)

4.00 (2.00–7.25)

2.00 (1.00–4.00)

0.16

 Hb (g/100 mL)

14.1 ± 1.1

14.0 ± 1.0

14.4 ± 1.0

14.0 ± 1.2

0.25

 Creatinine (μmol/L)

72.0 ± 13.4

70.9 ± 13.7

74.6 ± 13.9

70.8 ± 8.3

0.52

 AST (U/L)

28.1 ± 10.1

28.2 ± 11.2

28.8 ± 9.5

24.9 ± 3.6

0.64

 ALT (U/L)

29.8 ± 19.5

28.6 ± 19.6

32.4 ± 22.0

29.6 ± 8.6

0.74

 CK (U/L)

78.2 ± 40.0

99.0 ± 48.1

66.4 ± 28.7

82.9 ± 42.5

0.08

Medication, n (%)

 Prednisolone

17 (32.1)

2 (8.3)

2 (25.0)

21 (24.7)

0.08

 NSAIDs

20 (37.7)

12 (50.0)

3 (37.5)

35 (41.2)

0.58

 sDMARDs

32 (60.4)

6 (25.0)

7 (87.5)

45 (52.9)

0.002

 bDMARDs

17 (32.1)

8 (33.3)

4 (50.0)

29 (34.1)

0.73

 a-HT medication

16 (30.2)

4 (16.7)

2 (25.0)

22 (25.9)

0.45

  1. RA rheumatoid arthritis, AS ankylosing spondylitis, PsA psoriatic arthritis, IQR interquartile range, DAS28 disease activity score in 28 joints, SD standard deviation, ASDAS ankylosing spondylitis disease activity score, CVD cardiovascular disease, BMI body mass index, TC total cholesterol, HDL-c high-density lipoprotein cholesterol, TG triglycerides, LDL-c low-density lipoprotein cholesterol, sBP systolic blood pressure, dBP diastolic blood pressure, HT hypertension (self-reported hypertension, blood pressure >140/90 mmHg or current use of antihypertensive medication), CP carotid plaque, ESR erythrocyte sedimentation rate, CRP C-reactive protein, Hb hemoglobin, AST aspartate aminotransferase, ALT alanine aminotransferase, CK creatine kinase, NSAIDs nonsteroidal anti-inflammatory drugs, DMARDs disease-modifying antirheumatic drug, sDMARDs synthetic DMARDs, bDMARDs biologic DMARDs, a-HT antihypertensive
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us